Mepolizumab Treatment in Severe Pediatric Asthma: First Multicentric Real-World Data
Klin Padiatr
.
2022 Sep;234(5):305-308.
doi: 10.1055/a-1717-2234.
Epub 2022 Mar 22.
Authors
Martin Wetzke
#
1
,
Dominik Funken
#
1
,
Frank O Ahrens
2
,
Monika Gappa
3
,
Gesine Hansen
1
,
Cordula Koerner-Rettberg
4
,
Holger Koester
5
,
Johannes Schulze
6
,
Nicolaus Schwerk
1
,
Stefan Zielen
6
,
Christine Happle
1
7
8
Affiliations
1
Pediatric Ped. Pneumology, Allergology, Neonatology, Hannover Medical School, Hannover, Germany.
2
Pediatrics, AKK Altona Children's Hospital, Hamburg, Germany.
3
Pediatrics, Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany.
4
Pediatrics, Children's Hospital Wesel, Wesel, Germany.
5
Pediatrics, Oldenburg Hospital University Department Pediatrics and Adolescent Medicine, Oldenburg, Germany.
6
Pediatric Pneumology, Hospital of the Goethe University Frankfurt Centre for Paediatrics and Adolescent Medicine, Frankfurt am Main, Germany.
7
Biomedical Research in Endstage and Obstruktive Lung Disease Hannover BREATH, German Center for Lung Research, Hannover, Germany.
8
Excellence Cluster Infection Research RESIST, Hannover, Germany.
#
Contributed equally.
PMID:
35319087
DOI:
10.1055/a-1717-2234
No abstract available
Publication types
Comment
MeSH terms
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Child
Humans
Treatment Outcome
Substances
Antibodies, Monoclonal, Humanized
mepolizumab